Search Result

Results for "

tumor immunogenicity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (9) Autophagy (1) Calmodulin (2) Checkpoint Kinase (Chk) (2) DNA Stain (1) DNA/RNA Synthesis (1) EGFR (1) Estrogen Receptor/ERR (1) Ferroptosis (2) G-quadruplex (1) HDAC (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Liposome (1) MAP3K (2) MAPKAPK2 (MK2) (2) MDM-2/p53 (1) Microtubule/Tubulin (1) Parasite (1) PD-1/PD-L1 (1) Proton Pump (1) Reactive Oxygen Species (2) Sodium Channel (1) Src (1) TrxR (2)
By Research Areas:	Cancer (18) Inflammation/Immunology (2)

By Targets:

Apoptosis (9)

Autophagy (1)

Calmodulin (2)

Checkpoint Kinase (Chk) (2)

DNA Stain (1)

DNA/RNA Synthesis (1)

EGFR (1)

Estrogen Receptor/ERR (1)

Ferroptosis (2)

G-quadruplex (1)

HDAC (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Liposome (1)

MAP3K (2)

MAPKAPK2 (MK2) (2)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Parasite (1)

PD-1/PD-L1 (1)

Proton Pump (1)

Reactive Oxygen Species (2)

Sodium Channel (1)

Src (1)

TrxR (2)

By Research Areas:

Cancer (18)

Inflammation/Immunology (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16129A

CBP-501 acetate	Calmodulin MAP3K MAPKAPK2 (MK2) Checkpoint Kinase (Chk)	Cancer
CBP-501 acetate, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser ²¹⁶-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC₅₀ values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 acetate is used for various types of cancer .

HY-153545

9-Amino-NeuAc	Liposome	Cancer
9-Amino-NeuAc is a substrate of synthase. 9-Amino-NeuAc can be converted to CMP9-amino-NeuAc, activated to the corresponding CMPglycoside and transferred to asialoglycoprotein. 9-Amino-NeuAc can be used to target liposome synthesis while modulating tumor surface immunogenicity .

HY-162863

ERK-MYD88 interaction inhibitor 1	Apoptosis	Cancer
ERK-MYD88 interaction inhibitor 1 is an ERK-MYD88 interaction inhibitor. ERK-MYD88 interaction inhibitor 1 can induce an HRI-mediated integrated stress response (ISR), leading to cancer cell-specific immunogenic cell apoptosis (apoptosis). ERK-MYD88 interaction inhibitor 1 can induce anti-tumor T cell responses in Lewis lung cancer mice, exhibiting anti-tumor activity .

HY-162958

Photosensitizer-6	Apoptosis TrxR	Cancer
Photosensitizer-6 (Compound 4) is a gold (I) complex and exhibits inhibitory activity against TrxR. Photosensitizer-6 induces apoptosis in 4T1 cell, targets and eradicates tumors through chemo-phototherapy and immunogenic cell death under light exposure. Photosensitizer-6 can be used for tumor imaging .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-170971

Src Inhibitor 4	Apoptosis Src	Cancer
Src Inhibitor 4 (Compound 18) is a derivative of KX-01 and an Src inhibitor. Src Inhibitor 4 can inhibit tumor cells, disrupt microtubules, and induce cell cycle arrest, apoptosis, and immunogenic cell death. After the introduction of phenolic or aniline functionality, Src Inhibitor 4 can serve as a payload attachment site for antibody-drug conjugates and has anti-tumor activity .

HY-16129

CBP-501	Calmodulin Checkpoint Kinase (Chk) MAPKAPK2 (MK2) MAP3K	Cancer
CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser ²¹⁶-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC₅₀ values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer .

HY-161693

Telomeric G4s ligand 1	G-quadruplex DNA/RNA Synthesis Apoptosis	Cancer
Telomeric G4s ligand 1 is a telomeric G-quadruplex ligand that stabilizes telomeric G4 and induces R-loop formation, leading to DNA damage responses. Telomeric G4s ligand 1 induces apoptosis and evokes immunogenic cell death (ICD) in tumor cells .

HY-13735H

Quinacrine acetate Acriquine acetate	Parasite Sodium Channel DNA Stain Apoptosis	Cancer
Quinacrine (Acriquine) acetate is a small molecule modulator of the cGAS-STING-TBK1 signaling pathway, possessing immune stimulatory activity. Quinacrine acetate has been explored for its potential therapeutic applications in enhancing anti-tumor immunity. Quinacrine acetate can improve the effectiveness of cancer immunotherapies by addressing the poor immunogenicity of various tumors. Quinacrine acetate also presents a promising strategy for overcoming the limitations associated with immune checkpoint inhibitors in cancer treatment.

HY-145414

DYSP-C34	Reactive Oxygen Species	Cancer
DYSP-C34 is a potent, biocompatible, and ultrasound (US)-triggered multifunctional molecular machine. DYSP-C34 has multiple favorable properties, such as improved lipophilic/hydrophilic balance, intensified US-induced ROS production capacity, and better cellular permeability, resulting in the excellent tumor target efficiency and notable sonodynamic therapy (SDT)-mediated tumor regression. DYSP-C34 exhibits mild immunogenicity by stimulating APCs directly .

HY-P99687

Latikafusp AMG 256	PD-1/PD-L1	Cancer
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .

HY-149631

HFY-4A	HDAC	Cancer
HFY-4A is a HDAC inhibitor. HFY-4A inhibits breast cancer cell proliferation, migration, and invasion, and induces cell apoptosis. HFY-4A induces immunogenic cell death (ICD). HFY-4A inhibits tumor growth in breast cancer xenograft mouse models .

HY-173178

LNS8801	Estrogen Receptor/ERR	Cancer
LNS8801 is an orally active agonist of the G protein-coupled estrogen receptor (GPER). By activating GPER, LNS8801 mediates downstream signaling pathways, such as promoting the production of cyclic adenosine monophosphate (cAMP) and activating the cAMP response element-binding protein (CREB) signaling, thereby exerting anti-tumor activities including inhibiting tumor cell proliferation, inducing cell differentiation, and enhancing tumor immunogenicity. LNS8801 can be used in the research of various cancers (e.g., melanoma, pancreatic cancer, colorectal cancer, lung cancer, etc.) and relevant studies exploring the roles of GPER in normal physiological and pathological processes .

HY-158775

Ferroptocide	Ferroptosis Apoptosis Autophagy	Cancer
Ferroptocide is a cell death inducer that triggers ferroptosis and has anti-tumor activity. Ferroptocide can induce oxidative stress, leading to G2/M cell cycle arrest and apoptosis activation in LNCaP cells, while also effectively inhibiting the cell viability of both LNCaP and TRAMP-C1 cells. Ferroptocide can be used to study its capability to induce mitochondrial autophagy and to trigger immunogenic cell death (ICD) in prostate cancer cells .

HY-162264

Tubulin polymerization/V-ATPase-IN-1	Microtubule/Tubulin Proton Pump Apoptosis	Inflammation/Immunology Cancer
Tubulin polymerization/V-ATPase-IN-1 (compound F10) is a Tubulin polymerization/V-ATPase inhibitor. Tubulin polymerization/V-ATPase-IN-1 shows robust antiproliferation activity against four human cancer cell lines, and exerts antiproliferative activity by inhibiting tubulin and V-ATPase. Tubulin polymerization/V-ATPase-IN-1 induces immunogenic cell death in addition to apoptosis, and inhibits tumor growth in an RM-1 homograft model with enhanced T lymphocyte infiltration .

HY-168492

TrxR/EGFR-IN-1	Ferroptosis EGFR TrxR Apoptosis	Cancer
TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor. TrxR/EGFR-IN-1 is active against both Gefitinib (HY-50895)-sensitive and resistant lung cancers, effectively inhibiting tumor proliferation and promoting apoptosis. TrxR/EGFR-IN-1 promotes the degradation of GPX4 protein through autophagolysosomal and proteasomal pathways, leading to ferroptosis. In addition, TrxR/EGFR-IN-1 can induce endoplasmic reticulum stress and trigger immunogenic cell death. TrxR/EGFR-IN-1 can be used for the research of Gefitinib (HY-50895)-resistant lung cancer .

HY-173023

IDOi-Pt(IV) prodrug-1	Apoptosis Indoleamine 2,3-Dioxygenase (IDO) Reactive Oxygen Species	Cancer
IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) .

Cat. No.	Product Name

HY-L172

Immunopotentiator Compound Library	109 compounds
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 109 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Immunopotentiator Compound Library

109 compounds

Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines.

MCE designs a unique collection of 109 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Cat. No.	Product Name	Target	Research Area

HY-16129A

CBP-501 acetate	Calmodulin MAP3K MAPKAPK2 (MK2) Checkpoint Kinase (Chk)	Cancer
CBP-501 acetate, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser ²¹⁶-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC₅₀ values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 acetate is used for various types of cancer .

HY-106187

MART-1 (27-35) (human)	Peptides	Inflammation/Immunology
MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL) .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-16129

CBP-501	Calmodulin Checkpoint Kinase (Chk) MAPKAPK2 (MK2) MAP3K	Cancer
CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser ²¹⁶-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC₅₀ values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer .

HY-P10491

MAGE A4 (230-239)	Peptides	Cancer
MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope that can activate T cells and trigger the killing of tumor cells expressing MAGE-A4. MAGE A4 (230-239) is used in the development of next-generation T cell-based immunotherapies .

Cat. No.	Product Name	Target	Research Area

HY-P99687

Latikafusp AMG 256	PD-1/PD-L1	Cancer
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.